|
1
|
Braunwald E: The path to an angiotensin
receptor antagonist-neprilysin inhibitor in the treatment of heart
failure. J Am Coll Cardiol. 65:1029–1041. 2015.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Khder Y, Shi V, McMurray JJV and Lefkowitz
MP: Sacubitril/valsartan (LCZ696) in heart failure. Handb Exp
Pharmacol. 243:133–165. 2017.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Solomon SD, Rizkala AR, Gong J, Wang W,
Anand IS, Ge J, Lam CSP, Maggioni AP, Martinez F, Packer M, et al:
Angiotensin receptor neprilysin inhibition in heart failure with
preserved ejection fraction: rationale and design of the PARAGON-HF
trial. JACC Heart Fail. 5:471–482. 2017.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Barghash MH and Desai AS: First-in-class
composite angiotensin receptor-neprilysin inhibitors (ARNI) in
practice. Clin Pharmacol Ther. 102:265–268. 2017.PubMed/NCBI View
Article : Google Scholar
|
|
5
|
Mann DL, Greene SJ, Givertz MM, Vader JM,
Starling RC, Ambrosy AP, Shah P, McNulty SE, Mahr C, Gupta D, et
al: Sacubitril/valsartan in advanced heart failure with reduced
ejection fraction: Rationale and design of the LIFE trial. JACC
Heart Fail. 8:789–799. 2020.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Yancy CW, Jessup M, Bozkurt B, Butler J,
Casey Jr DE, Colvin MM, Drazner MH, Filippatos G, Fonarow GC, et
al: 2016 ACC/AHA/HFSA focused update on new pharmacological therapy
for heart failure: An update of the 2013 ACCF/AHA guideline for the
management of heart failure: A report of the american college of
cardiology/american heart association task force on clinical
practice guidelines and the heart failure society of america. J Am
Coll Cardiol. 68:1476–1488. 2016.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Ponikowski P, Voors AA, Anker SD, Bueno H,
Cleland JGF, Coats AJS, Falk V, González-Juanatey JR, Harjola VP,
Jankowska EA, et al: 2016 ESC guidelines for the diagnosis and
treatment of acute and chronic heart failure: The task force for
the diagnosis and treatment of acute and chronic heart failure of
the european society of cardiology (ESC)developed with the special
contribution of the heart failure association (HFA) of the ESC. Eur
Heart J. 37:2129–2200. 2016.PubMed/NCBI View
Article : Google Scholar
|
|
8
|
Russo-Vorms L, Meyer P and Reny JL: [«
ARNI » (Angiotensin Receptor-Neprilysin Inhibitor): When, for whom
and how?]. Rev Med Suisse. 15:1882–1886. 2019.PubMed/NCBI(In French).
|
|
9
|
Tanai E and Frantz S: Pathophysiology of
heart failure. Compr Physiol. 6:187–214. 2015.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Pocock SJ, Ariti CA, McMurray JJ, Maggioni
A, Køber L, Squire IB, Swedberg K, Dobson J, Poppe KK, Whalley GA,
et al: Predicting survival in heart failure: A risk score based on
39 372 patients from 30 studies. Eur Heart J. 34:1404–1413.
2013.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Mele D, Nardozza M and Ferrari R: Left
ventricular ejection fraction and heart failure: An indissoluble
marriage? Eur J Heart Fail. 20:427–430. 2018.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Tognon AP, Foppa M, Luft VC, Chambless LE,
Lotufo P, El Aouar LM, Fernandes LP and Duncan BB: Reproducibility
of left ventricular mass by echocardiogram in the ELSA-Brasil. Arq
Bras Cardiol. 104:104–111. 2015.PubMed/NCBI View Article : Google Scholar
|
|
13
|
McMurray JJ, Packer M, Desai AS, Gong J,
Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg
K, et al: Angiotensin-neprilysin inhibition versus enalapril in
heart failure. N Engl J Med. 371:993–1004. 2014.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Lewis EF, Claggett BL, McMurray JJV,
Packer M, Lefkowitz MP, Rouleau JL, Liu J, Shi VC, Zile MR, Desai
AS, et al: Health-related quality of life outcomes in PARADIGM-HF.
Circ Heart Fail. 10(e003430)2017.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Böhm M, Young R, Jhund PS, Solomon SD,
Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Swedberg K,
et al: Systolic blood pressure, cardiovascular outcomes and
efficacy and safety of sacubitril/valsartan (LCZ696) in patients
with chronic heart failure and reduced ejection fraction: Results
from PARADIGM-HF. Eur Heart J. 38:1132–1143. 2017.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Velazquez EJ, Morrow DA, DeVore AD,
Ambrosy AP, Duffy CI, McCague K, Hernandez AF, Rocha RA and
Braunwald E: Rationale and design of the comParIson Of
sacubitril/valsartaN versus enalapril on effect on nt-pRo-bnp in
patients stabilized from an acute heart failure episode
(PIONEER-HF) trial. Am Heart J. 198:145–151. 2018.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Solomon SD, McMurray JJV, Anand IS, Ge J,
Lam CSP, Maggioni AP, Martinez F, Packer M, Pfeffer MA, Pieske B,
et al: PARAGON-HF investigators and committees.
Angiotensin-neprilysin inhibition in heart failure with preserved
ejection fraction. N Engl J Med. 381:1609–1620. 2019.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Solomon SD, Zile M, Pieske B, Voors A,
Shah A, Kraigher-Krainer E, Shi V, Bransford T, Takeuchi M, Gong J,
et al: The angiotensin receptor neprilysin inhibitor LCZ696 in
heart failure with preserved ejection fraction: A phase 2
double-blind randomised controlled trial. Lancet. 380:1387–1395.
2012.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Książczyk M and Lelonek M: Angiotensin
receptor/neprilysin inhibitor-a breakthrough in chronic heart
failure therapy: Summary of subanalysis on PARADIGM-HF trial
findings. Heart Fail Rev. 25:393–402. 2020.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Chng BLK, Hon JS, Chan H, Zheng Y, Gao F,
Teo LYL and Sim KLD: Safety and tolerability of
sacubitril/valsartan initiation in inpatient versus outpatient
setting: A retrospective real world study. Heart Lung Circ.
30:674–682. 2021.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Dani SS, Ganatra S and Vaduganathan M:
Angioedema with sacubitril/valsartan: Trial-level meta-analysis of
over 14,000 patients and real-world evidence to date. Int J
Cardiol. 323:188–191. 2021.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Ayalasomayajula S, Langenickel T, Pal P,
Boggarapu S and Sunkara G: Clinical pharmacokinetics of
sacubitril/valsartan (LCZ696):A novel angiotensin
receptor-neprilysin inhibitor. Clin Pharmacokinet. 56:1461–1478.
2017.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Flarakos J, Du Y, Bedman T, Al-Share Q,
Jordaan P, Chandra P, Albrecht D, Wang L, Gu H, Einolf HJ, et al:
Disposition and metabolism of ((14)C) Sacubitril/Valsartan
(formerly LCZ696) an angiotensin receptor neprilysin inhibitor, in
healthy subjects. Xenobiotica. 46:986–1000. 2016.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Writing Committee Members and ACC/AHA
Joint Committee Members. 2022 AHA/ACC/HFSA guideline for the
management of heart failure. J Card Fail. 28:e1–e167.
2022.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Authors/Task Force Members. McDonagh TA,
Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, Burri H, Butler
J, Čelutkienė J, et al: 2021 ESC guidelines for the diagnosis and
treatment of acute and chronic heart failure: Developed by the task
force for the diagnosis and treatment of acute and chronic heart
failure of the european society of cardiology (ESC). With the
special contribution of the heart failure association (HFA) of the
ESC. Eur J Heart Fail. 24:4–131. 2022.PubMed/NCBI View Article : Google Scholar
|
